Jul. 4 at 8:27 PM
$ALT congratulations again to those who bought more under
$4. I wish I had picked up more but am awaiting a large cash transfer this month and preparing to unload some dry powder. 🧬
Of my current investments: I still think
$NUVB is more likely to be bought soon although I don’t invest on BO prospects (I’ve worked in and with @BiopharmaRN BD for years - it’s damn hard to predict who will be bought and by whom).
However the egregious selloff has led to an incredible buying opportunity and a likelier probability of ALT being bought. Recall: AltImmune because 5 patients outperformed historical fibrosis norms- who may have been healthier based on the cohort descriptions (the overall group had 10% lower ALD as a reminder).
I’m buying more shares of this,
$TNXP ,
$NUVB ,
$JFBR , and
$IMRX while they’re still cheap. 👍
Do your own @DueDiligence , @Duediligence20 & @DueDiligence101 !
@Dilly__Dilly , @Dilly_Due , @DillyDillyTrades , @DueDillionaire : nice handles as well. 🚀
Biotech 🧫
